UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ⊠

Filed by a Party other than the Registrant \square

CHECK THE APPROPRIATE BOX:

□ Preliminary Proxy Statement

□ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

```
□ Definitive Proxy Statement
```

Definitive Additional Materials

□ Soliciting Material Under §240.14a-12



ImmunityBio, Inc.

(Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):

⊠ No fee required.

□ Fee paid previously with preliminary materials.

□ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

Your Vote Counts!

IMMUNITYBIO, INC.

2024 Annual Meeting Vote by June 10, 2024 11:59 PM Eastern Time



C ImmunityBio IMMUNITYBIO, INC. 3530 JOHN HOPKINS COURT SAN DIEGO, CA 92121

V45533-P12055

You invested in IMMUNITYBIO, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 11, 2024.

Get informed before you vote

View the Notice and Proxy Statement and 2023 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

ng Items	Board Recommends
Election of Directors	
Nominees:	
Patrick Soon-Shiong, M.D.	Ser For
Cheryl L. Cohen	Ser 500
Richard Adcock	Ser For
Michael D. Blaszyk	Ser For
John Owen Brennan	Ser For
Wesley Clark	Ser For
Linda Maxwell, M.D.	S For
Christobel Selecky	Ser For
Barry J. Simon, M.D.	S For
To approve an amendment to the Immunity Bio, Inc. 2015 Equity Incentive Plan to increase the number of shares of the company's common stock authorized for issuance under the plan by 19,900,000 shares.	S For
To approve, on an advisory (non-binding) basis, the compensation of our Named Executive Officers ("Say-on-Pay").	S For
To ratify the selection of Ernst & Young LLP as ImmunityBio's independent registered public accounting firm for the fiscal year ending December 31, 2024.	Ser 60
	Nominees: Patrick Soon-Shiong, M.D. Cheryl L. Cohen Richard Adcock Michael D. Blaszyk John Owen Brennan Wesley Clark Linda Maxwell, M.D. Christobel Selecky Barry J. Simon, M.D. To approve an amendment to the Immunity Bio, Inc. 2015 Equity Incentive Plan to increase the number of shares of the company's common stock authorized for issuance under the plan by 19,900,000 shares. To approve, on an advisory (non-binding) basis, the compensation of our Named Executive Officers ("Say-on-Pay"). To ratify the selection of Ernst & Young LLP as ImmunityBio's independent registered public accounting firm for the

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V45534-P12055